April 2009 Volume 6 Number 4
Visit Nature Reviews Urology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=65&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Urology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=46&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=70&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
*********************************************************************
Nature Reviews Urology Impact Factor: 2.104*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Nature Clinical Practice Urology is now Nature Reviews Urology.
Nature Reviews Urology brings the distinguished reputation of the
Nature Reviews series into the clinical sciences. The journal will
remain dedicated to publishing the latest advances urology.
For more information visit
http://links.ealert.nature.com/ctt?kn=78&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Focal therapy for prostate cancer
Peter T. Scardino
p175 | doi:10.1038/nrurol.2009.52
http://links.ealert.nature.com/ctt?kn=72&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Bladder cancer: Inequalities in bladder cancer survival
p177 | doi:10.1038/nrurol.2009.30
http://links.ealert.nature.com/ctt?kn=15&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Prostate cancer: Post-ADT PSA kinetics predict survival
p178 | doi:10.1038/nrurol.2009.32
http://links.ealert.nature.com/ctt?kn=20&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
PSA structure in prostate cancer
p178 | doi:10.1038/nrurol.2009.38
http://links.ealert.nature.com/ctt?kn=60&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Prostate cancer: Sexual activity link with prostate cancer
p179 | doi:10.1038/nrurol.2009.34
http://links.ealert.nature.com/ctt?kn=24&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
IN BRIEF
Prostate cancer | Sexual dysfunction | Urinary incontinence
p179 | doi:10.1038/nrurol.2009.44
http://links.ealert.nature.com/ctt?kn=82&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Testicular cancer: Marijuana use linked with testicular cancer
p180 | doi:10.1038/nrurol.2009.33
http://links.ealert.nature.com/ctt?kn=41&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Benign prostatic hyperplasia: Alfuzosin improves sexual function
p180 | doi:10.1038/nrurol.2009.36
http://links.ealert.nature.com/ctt?kn=35&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Risk factors: ED at young age predicts heart disease
p181 | doi:10.1038/nrurol.2009.35
http://links.ealert.nature.com/ctt?kn=26&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Pediatrics: Pediatric dysfunctional voiding treated with tamsulosin
p182 | doi:10.1038/nrurol.2009.39
http://links.ealert.nature.com/ctt?kn=86&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Pediatrics: Melamine ingestion and prematurity associated with urolithiasis
p182 | doi:10.1038/nrurol.2009.42
http://links.ealert.nature.com/ctt?kn=39&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Prostatitis: No benefit of [alpha]-blockers for chronic prostatitis
Florian M. E. Wagenlehner and Wolfgang Weidner
p183 | doi:10.1038/nrurol.2009.45
A randomized controlled trial has questioned the widespread use of the
[alpha]-blocker alfuzosin as an empirical treatment for chronic
prostatitis-chronic pelvic pain syndrome. Instead, only a small subgroup
of patients might benefit from this therapy.
http://links.ealert.nature.com/ctt?kn=22&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Prostate Cancer: Regeneration of interest in the prostate
Anne T. Collins and Norman J. Maitland
p184 | doi:10.1038/nrurol.2009.48
The growth of prostate acini from single cell implants in mice is a major
breakthrough. Such results have important clinical implications, and will
ultimately change the treatment paradigm for prostatic disease.
http://links.ealert.nature.com/ctt?kn=32&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Prostate cancer: Neither vitamin E nor selenium prevent prostate cancer
Naomi E. Allen and Timothy J. Key
p187 | doi:10.1038/nrurol.2009.47
Data on the value of dietary supplements in reducing the risk of developing
prostate cancer have been conflicting; however, two large randomized
trials have indicated that prostate cancer risk is not reduced by the
long-term use of vitamin E, vitamin C or selenium supplements.
http://links.ealert.nature.com/ctt?kn=45&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Pathology: The lottery of conventional prostate biopsy
Gerald L. Andriole
p188 | doi:10.1038/nrurol.2009.46
Increasing the number of prostate biopsy cores taken does not improve
diagnostic accuracy. Instead, urologists need to think in three dimensions
and use template guidance to improve cancer detection and characterization.
http://links.ealert.nature.com/ctt?kn=58&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Imaging techniques for prostate cancer: implications for focal therapy
Baris Turkbey, Peter A. Pinto and Peter L. Choyke
p191 | doi:10.1038/nrurol.2009.27
For patients who present with localized prostate cancer, focal therapy
could be a treatment option; however, accurate imaging of the prostate
is required for focal therapy to be viable. This Review by Turkbey et al.
discusses the conventional methods for imaging the prostate, the new
developments for targeted imaging, and the possible role of image-guided
biopsy and focal therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=90&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=96&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Pathologic basis of focal therapy for early-stage prostate cancer
Vladimir Mouraviev, Janice M. Mayes and Thomas J. Polascik
p205 | doi:10.1038/nrurol.2009.29
The selection of patients with prostate cancer who are suitable for focal
therapy remains a controversial topic. In this Review, Mouraviev and
colleagues discuss pathological insights into the biology of early-stage
disease, and highlight the critical role of three-dimensional prostate
mapping protocols in the localization of disease.
Abstract: http://links.ealert.nature.com/ctt?kn=31&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=74&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Sildenafil citrate for female sexual arousal disorder: a future possibility?
Corina Schoen and Gloria Bachmann
p216 | doi:10.1038/nrurol.2009.25
Female sexual arousal disorder (FSAD) is a common disorder encountered in
clinical practice, but no drugs for FSAD have been approved. In this Review,
Schoen and Bachmann discuss the use of sildenafil citrate, a
phosphodiesterase type-5 inhibitor, for FSAD treatment. They provide the
rationale for treatment, and discuss results of sildenafil citrate from
past clinical studies in women with FSAD.
Abstract: http://links.ealert.nature.com/ctt?kn=12&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=68&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
A case of high-risk penile epithelioid hemangioendothelioma
Alexei Wedmid, Timothy A. Masterson, Robert G. Maki and Paul Russo
p223 | doi:10.1038/nrurol.2009.26
This Case Study describes a 48-year-old man who was referred to a specialist
oncology center for management of presumed angiosarcoma. Further
investigation revealed high-risk penile epithelioid hemangioendothelioma.
This article highlights the spectrum of clinical behavior of this atypical
epithelioid vascular tumor, and provides possible treatment options for
low-risk and high-risk forms of this cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=88&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=19&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Integrative medicine: complementary therapies and supplements
Barrie R. Cassileth, Jyothirmai Gubili and K. Simon Yeung
p228 | doi:10.1038/nrurol.2009.41
Many patients with urologic disorders, particularly cancer, use
complementary therapies as adjuncts to mainstream treatment. Accumulating
evidence highlights the beneficial impact of supportive measures, such as
acupuncture, yoga, meditation and physical activity, on the symptoms of
patients with urologic disorders. These data, as well as studies of herbs
and other dietary supplements, are discussed here.
Abstract: http://links.ealert.nature.com/ctt?kn=61&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=71&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Attending the AUA Annual Meeting in Chicago, IL this month?
Visit us at Booth #916 to pick up your complimentary copy of
Nature Reviews Urology and other related journals from
Nature Publishing Group.
We hope to see you there!
http://links.ealert.nature.com/ctt?kn=49&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=25&m=32254894&r=MTc2NDg0NjM5NAS2&b=2&j=NDcyMDkxMzAS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
